{
  "success": true,
  "pagesUsed": [
    2,
    8,
    11,
    16,
    25
  ],
  "modelUsed": "gemini-3-flash-preview",
  "narrative": {
    "narrativeContents": [
      {
        "id": "nc_1",
        "name": "PROTOCOL SYNOPSIS",
        "text": "PROTOCOL SYNOPSIS",
        "order": 0,
        "instanceType": "NarrativeContent",
        "sectionNumber": "0",
        "sectionTitle": "PROTOCOL SYNOPSIS",
        "sectionType": {
          "id": "68e3431d-7260-47aa-ad43-393405e01a24",
          "code": "Synopsis",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Synopsis",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_2",
        "name": "BACKGROUND",
        "text": "BACKGROUND",
        "order": 1,
        "instanceType": "NarrativeContent",
        "sectionNumber": "1",
        "sectionTitle": "BACKGROUND",
        "sectionType": {
          "id": "eeb6e54b-64ae-47ad-9f32-86d5fff6154b",
          "code": "Introduction",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Introduction",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_2_1",
          "nci_2_2",
          "nci_2_3",
          "nci_2_4",
          "nci_2_5",
          "nci_2_6",
          "nci_2_7",
          "nci_2_8",
          "nci_2_9",
          "nci_2_10",
          "nci_2_11",
          "nci_2_12"
        ]
      },
      {
        "id": "nc_3",
        "name": "OBJECTIVES AND ENDPOINTS",
        "text": "OBJECTIVES AND ENDPOINTS",
        "order": 2,
        "instanceType": "NarrativeContent",
        "sectionNumber": "2",
        "sectionTitle": "OBJECTIVES AND ENDPOINTS",
        "sectionType": {
          "id": "199e3efe-93c7-4219-bff4-c5b687420c58",
          "code": "Objectives",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Objectives",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_4",
        "name": "STUDY DESIGN",
        "text": "STUDY DESIGN",
        "order": 3,
        "instanceType": "NarrativeContent",
        "sectionNumber": "3",
        "sectionTitle": "STUDY DESIGN",
        "sectionType": {
          "id": "49470eac-e658-49c6-aeac-75b16c7da245",
          "code": "Study Design",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Study Design",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_4_1",
          "nci_4_2",
          "nci_4_3",
          "nci_4_4",
          "nci_4_5",
          "nci_4_6",
          "nci_4_7",
          "nci_4_8",
          "nci_4_9",
          "nci_4_10",
          "nci_4_11"
        ]
      },
      {
        "id": "nc_5",
        "name": "Target Population",
        "text": "Target Population",
        "order": 4,
        "instanceType": "NarrativeContent",
        "sectionNumber": "4",
        "sectionTitle": "Target Population",
        "sectionType": {
          "id": "47ca7994-5f06-4104-932b-a029e835c47b",
          "code": "Eligibility Criteria",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Eligibility Criteria",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_5_1"
        ]
      },
      {
        "id": "nc_6",
        "name": "Dissemination of Data and Protection of Trade Secrets",
        "text": "Dissemination of Data and Protection of Trade Secrets",
        "order": 5,
        "instanceType": "NarrativeContent",
        "sectionNumber": "9.5",
        "sectionTitle": "Dissemination of Data and Protection of Trade Secrets",
        "sectionType": {
          "id": "90d261ea-fba1-4403-b580-049e220347f8",
          "code": "Ethics",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Ethics",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_7",
        "name": "Protocol Amendments",
        "text": "Protocol Amendments",
        "order": 6,
        "instanceType": "NarrativeContent",
        "sectionNumber": "9.6",
        "sectionTitle": "Protocol Amendments",
        "sectionType": {
          "id": "31b81f84-f9a8-40d9-aa3e-019ec1f3910a",
          "code": "Ethics",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Ethics",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_8",
        "name": "REFERENCES",
        "text": "REFERENCES",
        "order": 7,
        "instanceType": "NarrativeContent",
        "sectionNumber": "10",
        "sectionTitle": "REFERENCES",
        "sectionType": {
          "id": "e917c4dc-4d7b-44c6-8ac2-671b69dbd207",
          "code": "References",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "References",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_9",
        "name": "Schedule of Activities",
        "text": "Schedule of Activities",
        "order": 8,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 1",
        "sectionTitle": "Schedule of Activities",
        "sectionType": {
          "id": "65225931-1a08-4721-a755-21d3175ec7c6",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_10",
        "name": "Schedule of Biomarker, Pharmacokinetic, and Immunogenicity Samples",
        "text": "Schedule of Biomarker, Pharmacokinetic, and Immunogenicity Samples",
        "order": 9,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 2",
        "sectionTitle": "Schedule of Biomarker, Pharmacokinetic, and Immunogenicity Samples",
        "sectionType": {
          "id": "5bca32ab-7367-4aa7-b592-c59a61a7553f",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_11",
        "name": "Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)",
        "text": "Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)",
        "order": 10,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 3",
        "sectionTitle": "Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)",
        "sectionType": {
          "id": "fa0e661b-e646-4908-a671-01cfa0f31c6a",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_12",
        "name": "Immune-Modified Response Evaluation Criteria in Solid Tumors (imRECIST)",
        "text": "Immune-Modified Response Evaluation Criteria in Solid Tumors (imRECIST)",
        "order": 11,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 4",
        "sectionTitle": "Immune-Modified Response Evaluation Criteria in Solid Tumors (imRECIST)",
        "sectionType": {
          "id": "7e746941-c8b6-4a1b-ae45-23b8f55796ec",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_13",
        "name": "European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire: EORTC QLQ-C30",
        "text": "European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire: EORTC QLQ-C30",
        "order": 12,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 5",
        "sectionTitle": "European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire: EORTC QLQ-C30",
        "sectionType": {
          "id": "322b0e0d-65d0-4140-85f1-cfbd09fcb92f",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_14",
        "name": "EORTC QLQ-HCC18 Module",
        "text": "EORTC QLQ-HCC18 Module",
        "order": 13,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 6",
        "sectionTitle": "EORTC QLQ-HCC18 Module",
        "sectionType": {
          "id": "82802441-3775-40d0-ae58-87a4cec7cd64",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_15",
        "name": "EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L)",
        "text": "EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L)",
        "order": 14,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 7",
        "sectionTitle": "EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L)",
        "sectionType": {
          "id": "d6a468c8-79f5-4e2a-91cd-8de369262ab4",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_16",
        "name": "Preexisting Autoimmune Diseases and Immune Deficiencies",
        "text": "Preexisting Autoimmune Diseases and Immune Deficiencies",
        "order": 15,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 8",
        "sectionTitle": "Preexisting Autoimmune Diseases and Immune Deficiencies",
        "sectionType": {
          "id": "f249201b-3014-4632-88ae-0cbdd36f4d03",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_17",
        "name": "Anaphylaxis Precautions",
        "text": "Anaphylaxis Precautions",
        "order": 16,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 9",
        "sectionTitle": "Anaphylaxis Precautions",
        "sectionType": {
          "id": "4fb11bc3-ff70-48d0-8992-5bd20d0713b6",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_18",
        "name": "Child-Pugh Classification",
        "text": "Child-Pugh Classification",
        "order": 17,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 10",
        "sectionTitle": "Child-Pugh Classification",
        "sectionType": {
          "id": "198f3c84-3616-4334-b318-8505b9231d4c",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      }
    ],
    "narrativeContentItems": [
      {
        "id": "nci_2_1",
        "name": "Background on Hepatocellular Carcinoma",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.1",
        "sectionTitle": "Background on Hepatocellular Carcinoma"
      },
      {
        "id": "nci_2_2",
        "name": "Current Systemic Treatment for Advanced Hepatocellular Carcinoma",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2",
        "sectionTitle": "Current Systemic Treatment for Advanced Hepatocellular Carcinoma"
      },
      {
        "id": "nci_2_3",
        "name": "Background on Atezolizumab",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.3",
        "sectionTitle": "Background on Atezolizumab"
      },
      {
        "id": "nci_2_4",
        "name": "Background on Bevacizumab",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.4",
        "sectionTitle": "Background on Bevacizumab"
      },
      {
        "id": "nci_2_5",
        "name": "Overview of Clinical Development Program in Hepatocellular Carcinoma",
        "text": "",
        "order": 4,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.5",
        "sectionTitle": "Overview of Clinical Development Program in Hepatocellular Carcinoma"
      },
      {
        "id": "nci_2_6",
        "name": "Atezolizumab Monotherapy",
        "text": "",
        "order": 5,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.5.1",
        "sectionTitle": "Atezolizumab Monotherapy"
      },
      {
        "id": "nci_2_7",
        "name": "Bevacizumab Monotherapy",
        "text": "",
        "order": 6,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.5.2",
        "sectionTitle": "Bevacizumab Monotherapy"
      },
      {
        "id": "nci_2_8",
        "name": "Study Rationale and Benefit-Risk Assessment",
        "text": "",
        "order": 7,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.6",
        "sectionTitle": "Study Rationale and Benefit-Risk Assessment"
      },
      {
        "id": "nci_2_9",
        "name": "Rationale for the Combination of Anti-PD-L1 and Anti-VEGF Therapy in Hepatocellular Carcinoma",
        "text": "",
        "order": 8,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.6.1",
        "sectionTitle": "Rationale for the Combination of Anti-PD-L1 and Anti-VEGF Therapy in Hepatocellular Carcinoma"
      },
      {
        "id": "nci_2_10",
        "name": "Clinical Data of Atezolizumab in Combination with Bevacizumab in Hepatocellular Carcinoma",
        "text": "",
        "order": 9,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.6.2",
        "sectionTitle": "Clinical Data of Atezolizumab in Combination with Bevacizumab in Hepatocellular Carcinoma"
      },
      {
        "id": "nci_2_11",
        "name": "COVID-19 Considerations",
        "text": "",
        "order": 10,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.6.3",
        "sectionTitle": "COVID-19 Considerations"
      },
      {
        "id": "nci_2_12",
        "name": "Summary",
        "text": "",
        "order": 11,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.6.4",
        "sectionTitle": "Summary"
      },
      {
        "id": "nci_4_1",
        "name": "Description of the Study",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.1",
        "sectionTitle": "Description of the Study"
      },
      {
        "id": "nci_4_2",
        "name": "Overview of Study Design",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.1.1",
        "sectionTitle": "Overview of Study Design"
      },
      {
        "id": "nci_4_3",
        "name": "Independent Data Monitoring Committee",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.1.2",
        "sectionTitle": "Independent Data Monitoring Committee"
      },
      {
        "id": "nci_4_4",
        "name": "End of Study",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.2",
        "sectionTitle": "End of Study"
      },
      {
        "id": "nci_4_5",
        "name": "Rationale for Study Design",
        "text": "",
        "order": 4,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.3",
        "sectionTitle": "Rationale for Study Design"
      },
      {
        "id": "nci_4_6",
        "name": "Rationale for Atezolizumab Dose and Schedule",
        "text": "",
        "order": 5,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.3.1",
        "sectionTitle": "Rationale for Atezolizumab Dose and Schedule"
      },
      {
        "id": "nci_4_7",
        "name": "Rationale for Bevacizumab Dose and Schedule",
        "text": "",
        "order": 6,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.3.2",
        "sectionTitle": "Rationale for Bevacizumab Dose and Schedule"
      },
      {
        "id": "nci_4_8",
        "name": "Rationale for Patient Population",
        "text": "",
        "order": 7,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.3.3",
        "sectionTitle": "Rationale for Patient Population"
      },
      {
        "id": "nci_4_9",
        "name": "Rationale for Control Arm",
        "text": "",
        "order": 8,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.3.4",
        "sectionTitle": "Rationale for Control Arm"
      },
      {
        "id": "nci_4_10",
        "name": "Rationale for Open-Label Study",
        "text": "",
        "order": 9,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.3.5",
        "sectionTitle": "Rationale for Open-Label Study"
      },
      {
        "id": "nci_4_11",
        "name": "Rationale for Overall Survival and Progression-Free Survival as Co-Primary Endpoints",
        "text": "",
        "order": 10,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.3.6",
        "sectionTitle": "Rationale for Overall Survival and Progression-Free Survival as Co-Primary Endpoints"
      },
      {
        "id": "nci_5_1",
        "name": "Inclusion Criteria",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.1",
        "sectionTitle": "Inclusion Criteria"
      }
    ],
    "abbreviations": [
      {
        "id": "abbr_1",
        "abbreviatedText": "16W-DCR",
        "expandedText": "disease-control rate at 16 weeks",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_2",
        "abbreviatedText": "AASLD",
        "expandedText": "American Association for the Study of Liver Diseases",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_3",
        "abbreviatedText": "ADA",
        "expandedText": "anti-drug antibody",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_4",
        "abbreviatedText": "AFP",
        "expandedText": "α-fetoprotein",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_5",
        "abbreviatedText": "ALP",
        "expandedText": "alkaline phosphatase",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_6",
        "abbreviatedText": "ALT",
        "expandedText": "alanine aminotransferase",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_7",
        "abbreviatedText": "ANC",
        "expandedText": "absolute neutrophil count",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_8",
        "abbreviatedText": "APASL",
        "expandedText": "Asian-Pacific Association for the Study of the Liver",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_9",
        "abbreviatedText": "ASCO",
        "expandedText": "American Society of Clinical Oncology",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_10",
        "abbreviatedText": "AST",
        "expandedText": "aspartate aminotransferase",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_11",
        "abbreviatedText": "BID",
        "expandedText": "twice a day",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_12",
        "abbreviatedText": "BP",
        "expandedText": "blood pressure",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_13",
        "abbreviatedText": "CDE",
        "expandedText": "Center of Drug Evaluation (China)",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_14",
        "abbreviatedText": "COPD",
        "expandedText": "chronic obstructive pulmonary disease",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_15",
        "abbreviatedText": "CR",
        "expandedText": "complete response",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_16",
        "abbreviatedText": "CRC",
        "expandedText": "carcinoma of the colon or rectum",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_17",
        "abbreviatedText": "CSR",
        "expandedText": "Clinical Study Report",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_18",
        "abbreviatedText": "CT",
        "expandedText": "computed tomography",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_19",
        "abbreviatedText": "DOR",
        "expandedText": "duration of response",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_20",
        "abbreviatedText": "EC",
        "expandedText": "Ethics Committee",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_21",
        "abbreviatedText": "ECOG",
        "expandedText": "Eastern Cooperative Oncology Group",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_22",
        "abbreviatedText": "eCRF",
        "expandedText": "electronic Case Report Form",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_23",
        "abbreviatedText": "EDC",
        "expandedText": "electronic data capture",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_24",
        "abbreviatedText": "EGD",
        "expandedText": "esophagogastroduodenoscopy",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_25",
        "abbreviatedText": "EOC",
        "expandedText": "epithelial ovarian cancer",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_26",
        "abbreviatedText": "EORTC",
        "expandedText": "European Organisation for Research and Treatment of Cancer",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_27",
        "abbreviatedText": "EQ-5D-5L",
        "expandedText": "EuroQol 5-Dimension, 5-Level Questionnaire",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_28",
        "abbreviatedText": "FDA",
        "expandedText": "(U.S.) Food and Drug Administration",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_29",
        "abbreviatedText": "FFPE",
        "expandedText": "formalin-fixed, paraffin-embedded",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_30",
        "abbreviatedText": "FPI",
        "expandedText": "first patient in",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_31",
        "abbreviatedText": "FTC",
        "expandedText": "fallopian tube cancer",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_32",
        "abbreviatedText": "GBM",
        "expandedText": "glioblastoma multiforme",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_33",
        "abbreviatedText": "GHS",
        "expandedText": "global health status",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_34",
        "abbreviatedText": "GI",
        "expandedText": "gastrointestinal",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_35",
        "abbreviatedText": "HBcAb",
        "expandedText": "hepatitis B core antibody",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_36",
        "abbreviatedText": "HBsAg",
        "expandedText": "hepatitis B surface antigen",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_37",
        "abbreviatedText": "HBV",
        "expandedText": "hepatitis B virus",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_38",
        "abbreviatedText": "HCC",
        "expandedText": "hepatocellular carcinoma",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_39",
        "abbreviatedText": "HCV",
        "expandedText": "hepatitis C virus",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_40",
        "abbreviatedText": "HIPAA",
        "expandedText": "Health Insurance Portability and Accountability Act",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_41",
        "abbreviatedText": "ICF",
        "expandedText": "Informed Consent Form",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_42",
        "abbreviatedText": "imRECIST",
        "expandedText": "Immune-Modified Response Evaluation Criteria in Solid Tumors",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_43",
        "abbreviatedText": "IRF",
        "expandedText": "Independent Review Facility",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_44",
        "abbreviatedText": "NCI CTCAE",
        "expandedText": "National Cancer Institute Common Terminology Criteria for Adverse Events",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_45",
        "abbreviatedText": "OR",
        "expandedText": "objective response",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_46",
        "abbreviatedText": "OS",
        "expandedText": "overall survival",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_47",
        "abbreviatedText": "PD-L1",
        "expandedText": "programmed death-ligand 1",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_48",
        "abbreviatedText": "PFS",
        "expandedText": "progression-free survival",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_49",
        "abbreviatedText": "QLQ-C30",
        "expandedText": "Quality-of-Life Questionnaire",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_50",
        "abbreviatedText": "RECIST v1.1",
        "expandedText": "Response Evaluation Criteria in Solid Tumors, Version 1.1",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_51",
        "abbreviatedText": "TTP",
        "expandedText": "time to progression",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_52",
        "abbreviatedText": "ULN",
        "expandedText": "upper limit of normal",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_53",
        "abbreviatedText": "VEGF",
        "expandedText": "vascular endothelial growth factor",
        "instanceType": "Abbreviation"
      }
    ],
    "summary": {
      "sectionCount": 18,
      "itemCount": 24,
      "abbreviationCount": 53
    },
    "studyDefinitionDocument": {
      "id": "sdd_1",
      "name": "A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB IN COMBINATION WITH BEVACIZUMAB COMPARED WITH SORAFENIB IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA",
      "documentType": "Protocol",
      "language": "en",
      "instanceType": "StudyDefinitionDocument",
      "version": "6",
      "contentIds": [
        "nc_1",
        "nc_2",
        "nc_3",
        "nc_4",
        "nc_5",
        "nc_6",
        "nc_7",
        "nc_8",
        "nc_9",
        "nc_10",
        "nc_11",
        "nc_12",
        "nc_13",
        "nc_14",
        "nc_15",
        "nc_16",
        "nc_17",
        "nc_18"
      ]
    }
  },
  "rawResponse": {
    "abbreviations": {
      "abbreviations": [
        {
          "abbreviation": "16W-DCR",
          "expansion": "disease-control rate at 16 weeks"
        },
        {
          "abbreviation": "AASLD",
          "expansion": "American Association for the Study of Liver Diseases"
        },
        {
          "abbreviation": "ADA",
          "expansion": "anti-drug antibody"
        },
        {
          "abbreviation": "AFP",
          "expansion": "α-fetoprotein"
        },
        {
          "abbreviation": "ALP",
          "expansion": "alkaline phosphatase"
        },
        {
          "abbreviation": "ALT",
          "expansion": "alanine aminotransferase"
        },
        {
          "abbreviation": "ANC",
          "expansion": "absolute neutrophil count"
        },
        {
          "abbreviation": "APASL",
          "expansion": "Asian-Pacific Association for the Study of the Liver"
        },
        {
          "abbreviation": "ASCO",
          "expansion": "American Society of Clinical Oncology"
        },
        {
          "abbreviation": "AST",
          "expansion": "aspartate aminotransferase"
        },
        {
          "abbreviation": "BID",
          "expansion": "twice a day"
        },
        {
          "abbreviation": "BP",
          "expansion": "blood pressure"
        },
        {
          "abbreviation": "CDE",
          "expansion": "Center of Drug Evaluation (China)"
        },
        {
          "abbreviation": "COPD",
          "expansion": "chronic obstructive pulmonary disease"
        },
        {
          "abbreviation": "CR",
          "expansion": "complete response"
        },
        {
          "abbreviation": "CRC",
          "expansion": "carcinoma of the colon or rectum"
        },
        {
          "abbreviation": "CSR",
          "expansion": "Clinical Study Report"
        },
        {
          "abbreviation": "CT",
          "expansion": "computed tomography"
        },
        {
          "abbreviation": "DOR",
          "expansion": "duration of response"
        },
        {
          "abbreviation": "EC",
          "expansion": "Ethics Committee"
        },
        {
          "abbreviation": "ECOG",
          "expansion": "Eastern Cooperative Oncology Group"
        },
        {
          "abbreviation": "eCRF",
          "expansion": "electronic Case Report Form"
        },
        {
          "abbreviation": "EDC",
          "expansion": "electronic data capture"
        },
        {
          "abbreviation": "EGD",
          "expansion": "esophagogastroduodenoscopy"
        },
        {
          "abbreviation": "EOC",
          "expansion": "epithelial ovarian cancer"
        },
        {
          "abbreviation": "EORTC",
          "expansion": "European Organisation for Research and Treatment of Cancer"
        },
        {
          "abbreviation": "EQ-5D-5L",
          "expansion": "EuroQol 5-Dimension, 5-Level Questionnaire"
        },
        {
          "abbreviation": "FDA",
          "expansion": "(U.S.) Food and Drug Administration"
        },
        {
          "abbreviation": "FFPE",
          "expansion": "formalin-fixed, paraffin-embedded"
        },
        {
          "abbreviation": "FPI",
          "expansion": "first patient in"
        },
        {
          "abbreviation": "FTC",
          "expansion": "fallopian tube cancer"
        },
        {
          "abbreviation": "GBM",
          "expansion": "glioblastoma multiforme"
        },
        {
          "abbreviation": "GHS",
          "expansion": "global health status"
        },
        {
          "abbreviation": "GI",
          "expansion": "gastrointestinal"
        },
        {
          "abbreviation": "HBcAb",
          "expansion": "hepatitis B core antibody"
        },
        {
          "abbreviation": "HBsAg",
          "expansion": "hepatitis B surface antigen"
        },
        {
          "abbreviation": "HBV",
          "expansion": "hepatitis B virus"
        },
        {
          "abbreviation": "HCC",
          "expansion": "hepatocellular carcinoma"
        },
        {
          "abbreviation": "HCV",
          "expansion": "hepatitis C virus"
        },
        {
          "abbreviation": "HIPAA",
          "expansion": "Health Insurance Portability and Accountability Act"
        },
        {
          "abbreviation": "ICF",
          "expansion": "Informed Consent Form"
        },
        {
          "abbreviation": "imRECIST",
          "expansion": "Immune-Modified Response Evaluation Criteria in Solid Tumors"
        },
        {
          "abbreviation": "IRF",
          "expansion": "Independent Review Facility"
        },
        {
          "abbreviation": "NCI CTCAE",
          "expansion": "National Cancer Institute Common Terminology Criteria for Adverse Events"
        },
        {
          "abbreviation": "OR",
          "expansion": "objective response"
        },
        {
          "abbreviation": "OS",
          "expansion": "overall survival"
        },
        {
          "abbreviation": "PD-L1",
          "expansion": "programmed death-ligand 1"
        },
        {
          "abbreviation": "PFS",
          "expansion": "progression-free survival"
        },
        {
          "abbreviation": "QLQ-C30",
          "expansion": "Quality-of-Life Questionnaire"
        },
        {
          "abbreviation": "RECIST v1.1",
          "expansion": "Response Evaluation Criteria in Solid Tumors, Version 1.1"
        },
        {
          "abbreviation": "TTP",
          "expansion": "time to progression"
        },
        {
          "abbreviation": "ULN",
          "expansion": "upper limit of normal"
        },
        {
          "abbreviation": "VEGF",
          "expansion": "vascular endothelial growth factor"
        }
      ]
    },
    "structure": {
      "document": {
        "title": "A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB IN COMBINATION WITH BEVACIZUMAB COMPARED WITH SORAFENIB IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA",
        "version": "6",
        "versionDate": null
      },
      "sections": [
        {
          "number": "0",
          "title": "PROTOCOL SYNOPSIS",
          "type": "Synopsis"
        },
        {
          "number": "1",
          "title": "BACKGROUND",
          "type": "Introduction",
          "subsections": [
            {
              "number": "1.1",
              "title": "Background on Hepatocellular Carcinoma"
            },
            {
              "number": "1.2",
              "title": "Current Systemic Treatment for Advanced Hepatocellular Carcinoma"
            },
            {
              "number": "1.3",
              "title": "Background on Atezolizumab"
            },
            {
              "number": "1.4",
              "title": "Background on Bevacizumab"
            },
            {
              "number": "1.5",
              "title": "Overview of Clinical Development Program in Hepatocellular Carcinoma"
            },
            {
              "number": "1.5.1",
              "title": "Atezolizumab Monotherapy"
            },
            {
              "number": "1.5.2",
              "title": "Bevacizumab Monotherapy"
            },
            {
              "number": "1.6",
              "title": "Study Rationale and Benefit-Risk Assessment"
            },
            {
              "number": "1.6.1",
              "title": "Rationale for the Combination of Anti-PD-L1 and Anti-VEGF Therapy in Hepatocellular Carcinoma"
            },
            {
              "number": "1.6.2",
              "title": "Clinical Data of Atezolizumab in Combination with Bevacizumab in Hepatocellular Carcinoma"
            },
            {
              "number": "1.6.3",
              "title": "COVID-19 Considerations"
            },
            {
              "number": "1.6.4",
              "title": "Summary"
            }
          ]
        },
        {
          "number": "2",
          "title": "OBJECTIVES AND ENDPOINTS",
          "type": "Objectives"
        },
        {
          "number": "3",
          "title": "STUDY DESIGN",
          "type": "Study Design",
          "subsections": [
            {
              "number": "3.1",
              "title": "Description of the Study"
            },
            {
              "number": "3.1.1",
              "title": "Overview of Study Design"
            },
            {
              "number": "3.1.2",
              "title": "Independent Data Monitoring Committee"
            },
            {
              "number": "3.2",
              "title": "End of Study"
            },
            {
              "number": "3.3",
              "title": "Rationale for Study Design"
            },
            {
              "number": "3.3.1",
              "title": "Rationale for Atezolizumab Dose and Schedule"
            },
            {
              "number": "3.3.2",
              "title": "Rationale for Bevacizumab Dose and Schedule"
            },
            {
              "number": "3.3.3",
              "title": "Rationale for Patient Population"
            },
            {
              "number": "3.3.4",
              "title": "Rationale for Control Arm"
            },
            {
              "number": "3.3.5",
              "title": "Rationale for Open-Label Study"
            },
            {
              "number": "3.3.6",
              "title": "Rationale for Overall Survival and Progression-Free Survival as Co-Primary Endpoints"
            }
          ]
        },
        {
          "number": "4",
          "title": "Target Population",
          "type": "Eligibility Criteria",
          "subsections": [
            {
              "number": "4.1",
              "title": "Inclusion Criteria"
            }
          ]
        },
        {
          "number": "9.5",
          "title": "Dissemination of Data and Protection of Trade Secrets",
          "type": "Ethics"
        },
        {
          "number": "9.6",
          "title": "Protocol Amendments",
          "type": "Ethics"
        },
        {
          "number": "10",
          "title": "REFERENCES",
          "type": "References"
        },
        {
          "number": "Appendix 1",
          "title": "Schedule of Activities",
          "type": "Appendix"
        },
        {
          "number": "Appendix 2",
          "title": "Schedule of Biomarker, Pharmacokinetic, and Immunogenicity Samples",
          "type": "Appendix"
        },
        {
          "number": "Appendix 3",
          "title": "Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)",
          "type": "Appendix"
        },
        {
          "number": "Appendix 4",
          "title": "Immune-Modified Response Evaluation Criteria in Solid Tumors (imRECIST)",
          "type": "Appendix"
        },
        {
          "number": "Appendix 5",
          "title": "European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire: EORTC QLQ-C30",
          "type": "Appendix"
        },
        {
          "number": "Appendix 6",
          "title": "EORTC QLQ-HCC18 Module",
          "type": "Appendix"
        },
        {
          "number": "Appendix 7",
          "title": "EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L)",
          "type": "Appendix"
        },
        {
          "number": "Appendix 8",
          "title": "Preexisting Autoimmune Diseases and Immune Deficiencies",
          "type": "Appendix"
        },
        {
          "number": "Appendix 9",
          "title": "Anaphylaxis Precautions",
          "type": "Appendix"
        },
        {
          "number": "Appendix 10",
          "title": "Child-Pugh Classification",
          "type": "Appendix"
        }
      ]
    }
  }
}